 | | Vol. 14.24 – 30 June, 2023 |
| |
|
|
| The synthesis of core-shell ordered mesoporous silica nanoparticles with tunable particle size and shape through a dual surfactant-assisted approach was demonstrated.
[Small] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that Collagen VI (Col VI) deposition correlated with stromal T cell density in human prostate cancer specimens. Motility of CD4+ T cells was completely ablated on purified Col VI surfaces when compared with Fibronectin and Collagen I.
[Matrix Biology] |
|
|
|
| Investigators identified a cell surface receptor neurokinin-1 (NK1R) as a clinically relevant driver of treatment-related neuroendocrine prostate cancer.
[Cell Death & Disease] |
|
|
|
| To understand the metabolic alterations involved in enzalutamide resistance, scientists performed metabolomic, transcriptomic, and cistromic analyses of enzalutamide-sensitive and -resistant prostate cancer cells, xenografts, patient-derived organoids, patient-derived explants, and tumors.
[Oncogene] |
|
|
|
| Researchers showed that tuft cells were upregulated early during prostate cancer development, and their numbers increased with progression.
[Oncogene] |
|
|
|
| The authors reported the discovery of ARD-2051 as a potent and orally efficacious androgen receptor proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM and Dmax over 90% in inducing AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines.
[European Journal Of Medicinal Chemistry] |
|
|
|
| Scientists investigated the anticancer effects of veratramine on androgen-independent prostate cancer using PC3 and DU145 cell lines, as well as a xenograft mouse model.
[American Journal Of Chinese Medicine] |
|
|
|
| Researchers synthesized seven ODAP-Urea-Lys derivatives characterized with p-bromobenzyl group conjugated to lysine. The ligands showed medium-to-high potency, with Ki values ranging from 27.9 nM to 0.94 nM.
[Bioorganic & Medicinal Chemistry Letters] |
|
|
|
| The in vitro antitumor effect of eight chromone-based compounds was evaluated in breast and prostate cancer cell lines, and in non-cancerous human mammary epithelial cells using a resazurin-based method.
[Chemistry & Biodiversity] |
|
|
|
|
| Immunotherapy, especially immune checkpoint inhibitors (ICIs), has made great progress in the treatment of various solid tumors, including prostate cancer. However, the ICIs have only shown modest outcomes in mCRPC compared with other tumors.
[Biochemical Pharmacology] |
|
|
|
|
| Andrew Goldstein, associate professor at the University of California, received a $900,000 Idea Development Award from the Department of Defense to study how metabolism changes in prostate cancer as a result of hormone therapy, the most commonly used treatment for men with advanced disease.
[University of California] |
|
|
|
| The National Health Service at Addenbrooke’s Hospital in Cambridge is now able to plan radiotherapy treatments faster than in the past, thanks to AI advances that are cutting wait times.
[Microsoft] |
|
|
|
|
| August 6 – 11, 2023
Newry, Maine, United States |
|
|
|
|
|
| | Arvinas, Inc. – New Haven, Connecticut, United States |
|
|
|
| | BC Cancer Center – Vancouver, British Columbia, Canada |
|
|
|
| | Cedars Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | Prostate Cancer UK – London, England, United Kingdom |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
